They should not be presented as standalone weight-loss treatments
E., Hussein, B., El-Seidi, E
Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
Kazak L, Chouchani ET, Jedrychowski MP, Erickson B, Shinoda K, Cohen P et al (2015) A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat
Personalized Medicine and Pharmacogenomics New Era of Diabetes Care: Pharmacogenomics for Personalized Medicine The dawn of personalized diabetes treatment combines studies of drugs with genomics to develop individualized medical regimens for patients
